Steinacker and colleagues found that serum GFAP levels, at a cut off 130 pg./ml, distinguished MDD from bipolar disorder and schizophrenia with a sensitivity and specificity of 87 and 70%, respectively (99). The gene discussed is GFAP; the disease is major depressive disorder.